miR-516a-3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNA-516a-3p (miR-516a-3p) is implicated in tumor suppression, but its role in breast cancer is not fully understood.
• The expression patterns and functional mechanisms of miR-516a-3p in breast cancer require further investigation.

Purpose of the Study:

• To elucidate the expression, function, and regulatory mechanisms of miR-516a-3p in breast cancer.
• To investigate the relationship between miR-516a-3p, Pygopus2 (Pygo2), and the Wnt/β-catenin pathway in breast cancer progression.

Main Methods:

• Quantitative real-time PCR and Western blot analysis to assess gene and protein expression.
• Dual luciferase reporter assay to confirm direct targeting.
• Cell proliferation, migration, and invasion assays.
• Epithelial-mesenchymal transition (EMT) analysis.
• Xenograft tumor models in mice.

Main Results:

• miR-516a-3p was significantly down-regulated, while Pygo2 was up-regulated in breast cancer tissues and cells.
• Low miR-516a-3p or high Pygo2 expression correlated with poor patient prognosis.
• Pygo2 was identified as a direct target of miR-516a-3p.
• miR-516a-3p overexpression inhibited breast cancer cell growth, migration, invasion, and EMT, whereas its down-regulation promoted these processes.
• miR-516a-3p suppressed breast cancer progression by inhibiting Pygo2 and subsequently activating the Wnt/β-catenin pathway.
• In vivo studies confirmed that miR-516a-3p inhibits tumor growth and EMT via the Pygo2/Wnt signaling pathway.

Conclusions:

• miR-516a-3p acts as a tumor suppressor in breast cancer by targeting Pygo2 and inhibiting the Wnt/β-catenin pathway.
• Restoring miR-516a-3p levels may offer a therapeutic strategy for breast cancer treatment.